Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.
Post-Conference Perspectives: Updates in HER2+ Metastatic Colorectal Cancer (mCRC); ASCO 2023 Highlights
An expert on colorectal cancer discusses the relationship between HER2 status and treatment selection and response.
Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.
An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.
Tanios S. Bekaii-Saab, MD, offers closing thoughts on the unmet needs and future of HER2+ metastatic colorectal cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5